Each of us knows someone with an Inflammatory, Diabetic or Degenerative Eye Disease. Current treatments for these diseases are unsatisfactory, and some, (such as the Dry form of Macular Degeneration, or “Dry AMD”) are currently untreatable. As a result, most people who suffer from these diseases experience progressively decreasing vision or lose their eyesight completely. These diseases are also prevalent among horses, certain breeds of dogs, and cats. While newer drugs show great promise, the natural “Blood-Eye Barrier” prevents most drugs from reaching the source of the inflammation inside the eye.
TheraKine is developing therapeutic systems to improve vision and prevent blindness. We recognize that inflammation is the common cause of vision loss in all serious eye diseases. Our pipeline of therapies attack inflammation by using clinically proven biologic drugs and small molecule inhibitors and packages them in Sustained Release Delivery Systems. These delivery systems will enable the drugs to be placed inside the Blood-Eye Barrier at the source of inflammation, and will last for several months, resulting in better outcomes, less side-effects and lower cost.